Stockhub

Biomea Fusion, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

15 August 2022

11 August 2022

27 July 2022

  • curprev 00:2500:25, 27 July 2022‎ Chris talk contribs‎ 474 bytes +474‎ Created page with "Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Biomea_Fusion,_Inc.’